UK-wide programme to boost success of immunotherapy
A team of UK universities, hospitals and industry, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust, have launched a new platform to understand immunotherapy response and side effects in cancer.
The programme will be funded by £9 ($11.7) million from the Medical Research Council and the Office for Life Sciences, and £12.9 ($16.8) million in matched funds from industry partners.
Although studies have shown that immunotherapy can completely eradicate advanced disease for some patients, the majority do not benefit, with many relapsing or experiencing significant side effects.
Even in melanoma, where immunotherapy is most successful, only 50% respond to immunotherapy.
The new UK-wide programme, titled Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity (MANIFEST), has been set up to evaluate the many barriers to the success of immunotherapy.
These include a lack of testable and usable biomarkers, which could reveal avenues for new treatments, like vaccines and cell therapies.
MANIFEST will aim to validate which biomarkers are present in patients before they start immunotherapy, and to develop tests that can monitor them during treatment.
The initial testing will include 3000 patients who have already completed their treatment and then 3000 who are starting treatment across the UK for breast, bladder, kidney and skin cancer, with plans to include additional cancer types as the programme expands.
Over four years, data will be collected from these patients, using procedures like blood tests, stool samples and tissue biopsies.
The team will analyse different aspects of cancerous tumours, including their genetic makeup, where they are in relation to immune cells, and what chemical signals they are producing. They will also generate a profile of immune cells in each patient’s bloodstream and analyse their gut microbiome.
Collaboration with industry
Professor Samra Turajlic, Project Lead, Clinical Group Leader at the Francis Crick Institute, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, and Associate Honorary Faculty at The Institute of Cancer Research, London, said: “In the last ten years we have made huge progress in the treatment of cancer with immunotherapy, but we are still underserving many patients due to treatment failure and side effects. Research on this scale can get us one step closer to better tests in the clinic, but also fuel more discoveries regarding cancer immunology and new therapies. Ultimately, we want to speed up the delivery of personalised medicine for a disease that affects huge numbers of people across the UK every year.”
MANIFEST will work with 11 industry partners: IMU Biosciences; Oxford Nanopore Technologies; Roche Pharma and Diagnostics divisions, and the Roche imCORE network; Molecule to Medicine; Guardant Health; Natera; Microbiotica; 10x Genomics; Akoya Biosciences, and Univ8 Genomics.
The consortium will also collaborate with AstraZeneca; Bristol Myers Squibb; Immunocore; MSD; Amazon Web Services, and Indica Labs.
Diana Spencer, Senior Digital Content Editor, DDW
